Invicta invictus Steven Joffe. Picture: Supplied
Industrial consumables business Invicta appears to be finding its way out of the stock market wilderness. Over one year the share has surged 369%, thanks to an aggressive clean-up under new management, which saw full-year headline earnings rocket 129% to 206c a share, debt slashed, and enough cash on hand to pay investors a 60c per share dividend. But, at R28, the company has a long way to go before it scales its 2013 share price peak of R110. The FM spoke to CEO Steven Joffe.
Clearly, Invicta had a much better year. Is that more to do with asset sales and cutbacks than operational improvements?
Invicta returns to profit in the year to March as restructuring pays off
iol.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iol.co.za Daily Mail and Mail on Sunday newspapers.
Data and safety review board reports how it monitored the COVID-19 vaccine trials
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
With Few New Clotting Cases, Johnson & Johnson Pause Could Be Lifted Soon
Top federal health officials said in interviews this week that the number of rare blood clotting disorders in recipients of the Johnson & Johnson vaccine has remained small.
Dr. Rochelle P. Walensky, the C.D.C. director, with Dr. Anthony S. Fauci, left, and David Kessler this month on Capitol Hill. Dr. Walensky said in an interview on Wednesday that federal officials had found “needles in haystacks,” an indication of how thorough the government’s oversight was.Credit.Pool photo by Susan Walsh
April 22, 2021Updated 6:29 p.m. ET
WASHINGTON Federal health officials are leaning toward lifting their recommended pause on the use of Johnson & Johnson’s coronavirus vaccine after finding only a limited number of additional cases of a rare blood clotting disorder among recipients.